News |
Date: 15.12.2021
| Ministry of Health and Care Services
The Norwegian Directorate of Health and the pharmaceutical company Merck Sharp & Dohme (MSD) entered into an agreement on Friday 11. December an agreement for the delivery of 8640 treatments of the antiviral drug molnupiravir before Christmas.
Norway also participates in pan-European procurement of drugs for the treatment of covid-19. An application for approval of the drug for MSD is now being processed by the European Medicines Agency (EMA). The Norwegian Directorate of Health has been commissioned to assess how the drug should be used in Norway, including which patients should be offered the drug. Currently, the Norwegian Directorate of Health considers that the use of the drug should await approval in the EU, but the Norwegian Directorate of Health is considering this on an ongoing basis.
Price and contract terms are confidential information.
– I am glad that we have reached a bilateral agreement on this drug. The agreement the Norwegian Directorate of Health has now entered into gives Norway access to the medicine even before a joint European agreement is in place, says Minister of Health and Care Services Ingvild Kjerkol.